Kymera Therapeutics, Inc. Common Stock (KYMR) Valuation
Historical valuation analysis based on 500 data points (2024-09-25 to 2026-09-23)
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health...
Kymera Therapeutics, Inc. Common Stock (KYMR) currently trades at a P/S ratio of 218.79 (range: 35.84–241.22, 94th percentile — expensive relative to its history).
Kymera Therapeutics, Inc. Common Stock trades well above its own historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/S Ratio | 218.79 | 35.84 | 96.51 | 241.22 | 94th | expensive relative to its history |
Kymera Therapeutics, Inc. Common Stock (KYMR) Valuation & P/E History
Kymera Therapeutics, Inc. Common Stock (KYMR) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry currently trading at $115.47 with a market capitalization of $9.6 billion. This page provides historical valuation analysis for KYMR based on 500 data points covering 2024-09-25 to 2026-09-23.. The P/S ratio of 218.79 compares to a median of 96.51.
KYMR Valuation Metrics & Historical Range
The valuation table above shows Kymera Therapeutics, Inc. Common Stock's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether KYMR is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests KYMR is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Kymera Therapeutics, Inc. Common Stock.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is KYMR Overvalued or Undervalued?
Kymera Therapeutics, Inc. Common Stock trades well above its own historical valuation range across most metrics. The overall valuation percentile of 94 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive KYMR is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full KYMR analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.KYMR trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.